Objective, reproducible, and trustworthy data in clinical trials with imaging endpoints

Dr. Anthony Tolcher, medical oncologist and CEO of NEXT Oncology, spoke to us about objectivity as one of the biggest challenges in clinical trials and how a software solution for tumor assessment can improve the quality and reproducibility of data, all while saving time.

Moreover, such software solutions are a key aspect for the approval of novel drugs based on small sample size – like for example targeted or tissue agnostic medicine, as a significant advance for precision therapies. Dr. Tolcher describes how mint Lesion™ assists in generating trustworthy data, “so that [one] can ensure that the drugs that are getting approved really do work.”

Click here or on the image above to watch the full video on YouTube.

Structured Reporting Clinical Trials Standardized Reading Procedures Therapy Response Assessment Video

Related Resources

Related Resources

Doctor looking at a medical image within the program mint Lesion

BZKF BORN Roll-Out Trainings in Full Swing

A first impression of the on-site BZKF BORN Roll-Out Trainings at LMU Klinikum München with our expert Steffen Rupp. The project is in full swing: the…

Picture shows a scan of pericardial effusion

RACOON: Study emphasizes the clinical relevance of pericardial effusion as an imaging biomarker in COVID-19 patients

A multicenter study [1] based on the German research infrastructure project RACOON (Radiological Cooperative Network of the COVID-19 pandemic; a Netzw…

Doctor looking at a CT scan in mint Lesion™

Software-Assisted CT Assessment Outperforms Manual Methods in Oncology Study

A recent study conducted at UKE Hamburg compared manual and software-assisted assessments of computed tomography (CT) scans according to iRECIST…